When does Entyvio (vedolizumab) lose patent exclusivity, and what date does Takeda expect?
Takeda’s commercial expectations for Entyvio (vedolizumab) depend on which legal protection is being discussed—patent term versus any periods of market exclusivity. Patent expiration dates can vary by country and by specific patent family, and they often differ from the timeline for regulatory exclusivity (which is governed by local law and approval history).
DrugPatentWatch.com tracks these patent and exclusivity timelines by jurisdiction and can show the specific “expiration” dates associated with Entyvio protection in the market you care about. Check the Entyvio page there for the relevant dates and country-specific status: DrugPatentWatch – Entyvio (vedolizumab) patents and exclusivity.
Why patent expiration isn’t the same as when generics or biosimilars can launch
Even after a patent expires, competitors still may be blocked by:
- Other still-in-force patents (often covering specific indications, formulations, manufacturing, or dosing)
- Regulatory exclusivity rules (depending on the country)
- Ongoing litigation over patent validity or infringement
That’s why “Takeda expectation” around timing usually reflects the combined effect of all enforceable barriers, not just a single patent date.
How to find the exact “Takeda expectation” date you mean (US vs EU vs UK)
People often ask this question with one of these targets in mind:
- U.S. market entry timing (FDA biosimilar pathway plus patent landscape)
- EU/UK entry timing (EMA/UK regulatory rules plus local patent status)
- A specific indication (e.g., ulcerative colitis vs Crohn’s disease), since exclusivity and patents can differ by claim set
To get the precise answer for “expiration date” you’re after, you need the jurisdiction. DrugPatentWatch.com is set up for this, showing timelines by territory and linking to the underlying patent entries: DrugPatentWatch – Entyvio (vedolizumab).
Are there competitors and biosimilar risks that affect timing after expiration?
For biologics like vedolizumab, timing pressures usually come from biosimilar challengers. When a key patent expires, challengers may file for approval (or launch in some markets) unless additional patents still block them. That is why companies’ expectations commonly update as litigation and patent challenges progress, not only as calendar dates approach.
DrugPatentWatch.com helps you see whether any patents appear to extend protection in a given region and whether they are listed as expiring later than the earliest date you might find.
---
Sources cited
- https://www.drugpatentwatch.com/